Key result
Quinidine and sotalol show individual-dependent antiarrhythmic effects in Brugada syndrome iPSC-CM models.
Why the study?
SCN5A genotype-phenotype correlations in Brugada syndrome are not completely matched, with clinical phenotypes of a single variant ranging from asymptomatic to sudden cardiac death.
Patient-specific iPSC-CMs reveal variable phenotypic severity in Brugada syndrome and demonstrate individual-dependent responses to antiarrhythmic drugs.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for individualized Brugada therapy; leaves open clinical translation of iPSC-CM screening.
BACKGROUND: Brugada syndrome (BrS) is a cardiac channelopathy that can result in sudden cardiac death (SCD). SCN5A is the most frequent gene linked to BrS, but the genotype-phenotype correlations are not completely matched. Clinical phenotypes of a particular SCN5A variant may range from asymptomatic to SCD. Here, we used comparison of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) derived from a SCN5A mutation-positive (D356Y) BrS family with severely affected proband, asymptomatic mutation carriers (AMCs) and healthy controls to investigate this variation. METHODS: 26 iPSC lines were generated from skin fibroblasts using nonintegrated Sendai virus. The generated iPSCs were differentiated into cardiomyocytes using a monolayer-based differentiation protocol. FINDINGS: currents. Moreover, drug screening using established BrS iPSC-CM models demonstrated that quinidine and sotalol possessed antiarrhythmic effects in an individual-dependent manner. Clinically, venous and oral administration of calcium partially reduced the malignant arrhythmic events of the proband in mid-term follow-up. INTERPRETATION: currents might be a compensatory mechanism to resist arrhythmogenesis in BrS AMCs. FUNDING: National Key R&D Program of China (2017YFA0103700), National Natural Science Foundation of China (81922006, 81870175), Natural Science Foundation of Zhejiang Province (LD21H020001, LR15H020001), National Natural Science Foundation of China (81970269), Key Research and Development Program of Zhejiang Province (2019C03022) and Natural Science Foundation of Zhejiang Province (LY16H020002).
No takes yet. Share an insight, caveat, or question.
Sun et al. (2023) studied Brugada syndrome. Drug screening (quinidine, sotalol) and calcium administration vs. Healthy controls and asymptomatic mutation carriers was evaluated on Antiarrhythmic effects and arrhythmic events. Drug screening using established Brugada syndrome iPSC-CM models demonstrated that quinidine and sotalol possessed antiarrhythmic effects in an individual-dependent manner.
Synapse has enriched 10 related papers. Consider them for comparative context: